Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 192Methotrexate 106Cytarabine 86fludarabine phosphate 80Busulfan 71Tacrolimus 70Peripheral Blood Stem Cell Transplantation 69Mycophenolic Acid 69Whole-Body Irradiation 68Vincristine 67fludarabine 61Filgrastim 61Etoposide 59Dexamethasone 54Melphalan 52Radiotherapy 47Rituximab 46Cyclosporine 46Doxorubicin 38Antilymphocyte Serum 37Thiotepa 35Prednisone 35Mercaptopurine 35Granulocyte Colony-Stimulating Factor 35blinatumomab 33pegaspargase 27Methylprednisolone 27Daunorubicin 26Clofarabine 26Asparaginase 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × BEBT-908 × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡